Cantor Fitzgerald doubled down on its bearish stance toward stocks on Monday, reaffirming its negative outlook with the statement, “we continue to be bearish on equities” in an investor note ...

Cantor Fitzgerald assumed coverage of Aclaris Therapeutics (ACRS) with an Overweight rating. Cantor is bullish on the TSLP and IL-4R bispecific, which looks differentiated, and even early proof-of ...

Cantor Fitzgerald analyst B. Knoblauch now expects that the company will post earnings per share of ($1.06) for the year, down from […] Skip to main content Analyst Ratings ...

Cantor Fitzgerald has a “Overweight” rating and a $790.00 price target on the stock. The consensus estimate for Meta Platforms’ current full-year earnings is $26.70 per share.

On Monday, Cantor Fitzgerald reaffirmed its Overweight rating on Cartesian Therapeutics (NASDAQ:RNAC), currently trading at $15.80, with a steady price target of $22.00. The stock has experienced ...

Cantor Fitzgerald upgraded Tesla (TSLA, Financials) to Overweight from Neutral, citing a buying opportunity following the recent sell-off, the firm announced after a site visit to Tesla's ...

On Wednesday, Cantor Fitzgerald outlined a strategic approach for investors in the smid cap biotech sector, emphasizing the importance of downside protection and the potential for significant upside.

Tesla (NASDAQ:TSLA) attracted an upgrade from Cantor Fitzgerald on Wednesday after the firm visited the company's Gigafactory and AI data centers in Austin. The firm moved Tesla (NASDAQ ...

Cantor Fitzgerald Large Cap Focused Fund earns an Above Average Process Pillar rating. The main driver of the rating is the parent firm's five-year risk-adjusted success ratio of 81%. The measure ...

March 31 (Reuters) - Analysts at Cantor Fitzgerald, formerly headed by the Trump administration's Secretary of Commerce Howard Lutnick, called for the dismissal of Secretary of Health and Human ...